SCHEMBL4190074

SCHEMBL4190074

CC(=COc1ccccc1-c1ccccc1)C(=O)OCCCOc1ccc(Cl)cc1OCCCOC(=O)C(C)=COc1ccccc1-c1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 1/20 0.42
KDM4E B2RXH2 11/20 0.41
L3MBTL1 Q9Y468 3/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
LMNA P02545 1/20 0.40
MAPT P10636 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
SLC6A9 P48067 1/20 0.39
ALDH1A1 P00352 5/20 0.39
PLA2G1B P04054 1/20 0.38
HTT P42858 1/20 0.38
ATG4B Q9Y4P1 1/20 0.38
GAA P10253 2/20 0.38
KCNA3 P22001 1/20 0.37
KMT2A Q03164 2/20 0.37
POLB P06746 1/20 0.37
MEN1 O00255 1/20 0.37
FABP3 P05413 1/20 0.37
FABP4 P15090 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4202057 0.90 KDM4E (0.49) KDM4EL3MBTL1SMN1; SMN2ALDH1A1HTT
SCHEMBL4193711 0.87 KDM4E (0.51) KDM4EL3MBTL1SMN1; SMN2ALDH1A1HTT
SCHEMBL4198447 0.84 PPARG (0.40) KDM4EL3MBTL1SMN1; SMN2ALDH1A1GAA
SCHEMBL4197864 0.84 FFAR4 (0.47) KDM4EL3MBTL1SMN1; SMN2TDP1ALDH1A1
SCHEMBL4197813 0.83 L3MBTL1 (0.42) KDM4EL3MBTL1SMN1; SMN2LMNAMAPT
SCHEMBL4186160 0.83 FFAR4 (0.47) KDM4EL3MBTL1SMN1; SMN2ALDH1A1HTT
SCHEMBL4197503 0.82 FFAR4 (0.48) KDM4ESMN1; SMN2TDP1ALDH1A1HTT
SCHEMBL4190846 0.81 KDM4E (0.40) KDM4EL3MBTL1SMN1; SMN2LMNATDP1
SCHEMBL4188678 0.78 FFAR4 (0.46) KDM4EL3MBTL1SMN1; SMN2ALDH1A1GAA
SCHEMBL4204186 0.77 PPARG (0.42) KDM4EL3MBTL1SMN1; SMN2LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1627867-B1 (METH)ACRYLIC ESTER COMPOUND AND USE THEREOF MITSUI CHEMICALS INC (JP) 2016-01-20 EP disclosed
US-7534909-B2 (Meth) acrylic ester compound and use thereof MITSUI CHEMICALS, INC. (JP) 2009-05-19 US disclosed
US-20070078198-A1 (Meth) acrylic ester compound and use thereof MITSUI CHEMICALS, INC. (JP) 2007-04-05 US disclosed
EP-1627867-A1 (METH)ACRYLIC ESTER COMPOUND AND USE THEREOF Mitsui Chemicals, Inc. (JP) 2006-02-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070078198-A1 (Meth) acrylic ester compound and use thereof METTL14, PAM, TAS2R41 PTGDR2 468/4885KDM4E 270/4885L3MBTL1 2124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.